Cleared Traditional

K093916 - NEOBASE NON-DERIVATIZED MSMS KIT MODEL 3040-001U (FDA 510(k) Clearance)

Aug 2010
Decision
244d
Days
Class 2
Risk

K093916 is an FDA 510(k) clearance for the NEOBASE NON-DERIVATIZED MSMS KIT MODEL 3040-001U. This device is classified as a System, Test, Amino Acids, Free Carnitines And Acylcarnitines Tandem Mass Spectrometry (Class II - Special Controls, product code NQL).

Submitted by Perkinelmer, Inc. (Indianapolis, US). The FDA issued a Cleared decision on August 23, 2010, 244 days after receiving the submission on December 22, 2009.

This device falls under the Chemistry FDA review panel. Regulated under 21 CFR 862.1055. Amino Acids, Free Carnitines And Acylcarnitines Test System Is Intended For The Measurement And Evaluation Of Amino Acid, Free Carnitine And Acylcarnitine Concentrations From Newborn Whole Blood Filter Paper Samples. The Quantitative Analysis Of The Amino Acids, Free Carnitines And Acylcarnitines And Their Relationship With Each Other Is Intended To Provide Analyte Concentration Profiles That Should Aid In Identifying Elevated Levels Of These Metabolites For Screening Newborns For One Or More Of Several Metabolic Disorders..

Submission Details

510(k) Number K093916 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 22, 2009
Decision Date August 23, 2010
Days to Decision 244 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF

Device Classification

Product Code NQL - System, Test, Amino Acids, Free Carnitines And Acylcarnitines Tandem Mass Spectrometry
Device Class Class II - Special Controls
CFR Regulation 21 CFR 862.1055
Definition Amino Acids, Free Carnitines And Acylcarnitines Test System Is Intended For The Measurement And Evaluation Of Amino Acid, Free Carnitine And Acylcarnitine Concentrations From Newborn Whole Blood Filter Paper Samples. The Quantitative Analysis Of The Amino Acids, Free Carnitines And Acylcarnitines And Their Relationship With Each Other Is Intended To Provide Analyte Concentration Profiles That Should Aid In Identifying Elevated Levels Of These Metabolites For Screening Newborns For One Or More Of Several Metabolic Disorders.